Shield Therapeutics is a commercial-stage pharmaceutical company whose lead compound, Feraccru, is marketed in some European markets for the treatment of iron deficiency, with or without anaemia. In a global market estimated to be worth c.£2.5bn, the recent head-to-head Phase IIIb trial, which showed Feraccru to be equivalent to the leading intravenous iron, positions Feraccru very favourably. The approval in the US, expected on 27 July, will be a key inflection point, the risk-adjusted
14 May 2019
Shield Therapeutics - Europe underpins current valuation; await US approval
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Europe underpins current valuation; await US approval
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
14 May 2019 -
Author:
Mark Brewer -
Pages:
36
Shield Therapeutics is a commercial-stage pharmaceutical company whose lead compound, Feraccru, is marketed in some European markets for the treatment of iron deficiency, with or without anaemia. In a global market estimated to be worth c.£2.5bn, the recent head-to-head Phase IIIb trial, which showed Feraccru to be equivalent to the leading intravenous iron, positions Feraccru very favourably. The approval in the US, expected on 27 July, will be a key inflection point, the risk-adjusted